Post-EHA 2026 CLL Highlights

Featuring presentations & discussions on selected CLL abstracts from the 31st Congress of the European Hematology Association (EHA).  

Chair: Alexey Danilov | Moderators: Othman Al-Sawaf, Catherine Coombs & Deborah Stephens

The Post-EHA 2026 CLL Highlights has been supported by AstraZeneca (Diamond Sponsor), Genentech (Silver Sponsor), and Nurix (Silver Sponsor). Supporters have no influence over the production of content.

Preliminary Agenda (subject to change)

Session 1: Advances with BTKis and BTK degraders  

Final results from ASSURE: A Phase 3B study of the safety and efficacy of acalabrutinib in patients with chronic lymphocytic lymphoma 
(Abstract PF598) | Speaker: TBC

Outcomes of venetoclax-based treatment in patients with Bruton tyrosine kinase inhibitor (BTKI)-treated chronic lymphocytic leukemia (CLL): An international study conducted by ERIC (Abstract S151) | Speaker: Thomas Chatzikonstantinou

Pirtobrutinib in treatment-naïve patients with CLL/SLL: Pooled results from BRUIN CLL-313 and BRUIN CLL-314 (Abstract PS1701) | Speaker: Jennifer Woyach

Updated efficacy and safety data from an ongoing Phase 1a/b trial of the BTK degrader bexobrutideg (NX-5948) in patients with CLL across lines of therapy (Abstract S150) | Speaker: Talha Munir

BGB-16673, a Bruton tyrosine kinase (BTK) degrader, in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL): A Phase 1 CADANCE-101 study update (Abstract S152) | Speaker: Stephan Stilgenbauer

Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated CLL/SLL: a Phase 3, randomized trial (BRUIN CLL-322) (Abstract LB5001) | Speaker: Matthew Davids

Panel discussion 

Session 2: Updates in frontline combination strategies for CLL 

A Phase 2 study of fixed-duration pirtobrutinib and obinutuzumab in previously untreated CLL (Abstract S148) | Speaker: Inhye Ahn

First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53 (Abstract S145) | Speaker: Chan Cheah

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: final results of the randomized CLL14 study (Abstract S146) | Speaker: TBC

Panel discussion 

Session 3: Latest with immunotherapy and cellular therapy in CLL 

Fixed duration venetoclax plus epcoritamab shows favorable tolerability and high response rates with early molecular responses in R/R CLL/SLL: Interim analysis of the randomized HOVON 165/AETHER trial (Abstract S153) | Speaker: Arnon Kater

Dual targeted lentiviral transduced anti-CD20/anti-CD19 (LV20.19) CAR T cells for relapsed, refractory CLL (Abstract S154) | Speaker: Nirav Shah

Panel discussion 

Conclusions and webinar close